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Aim: Several lines of evidence implicate glutamater-
gic dysfunction in the pathophysiology of
obsessive–compulsive disorder (OCD), presenting
this neurotransmitter as a target for the development
of novel pharmacotherapy. The objective of this
study was to assess the efﬁcacy of minocycline as an
augmentative agent to ﬂuvoxamine in the treatment
of patients with OCD.
Methods: One hundred and two patients with the
diagnosis of moderate-to-severe OCD were recruited
to this study. A randomized double-blind trial was
designed and patients received either L-carnosine or
placebo as adjuvant to ﬂuvoxamine for 10 weeks.
The patients randomly received either minocycline
100 mg twice per day or placebo for 10 weeks. All
patients received ﬂuvoxamine (100 mg/day) for the
ﬁrst 4 weeks, followed by 200 mg/day for the rest of
the trial, regardless of their treatment groups. Partici-
pants were evaluated using the Yale–Brown Obses-
sive Compulsive Scale (Y-BOCS). The main
outcome measure was to assess the efﬁcacy of mino-
cycline in improving the OCD symptoms.
Results: General linear model repeated measures
demonstrated signiﬁcant effect for time × treatment
interaction on the Y-BOCS total scores, F(1.49,
137.93) = 7.1, P = 0.003, and Y-BOCS Obsession
subscale score, F(1.54, 141.94) = 9.72, P = 0.001,
and near signiﬁcant effect for the Y-BOCS Compul-
sion subscale score, F(1.27, 117.47) = 2.92,
P = 0.08. A signiﬁcantly greater rate of partial and
complete response was observed in the minocycline
group (P < 0.001). The frequency of side-effects
was not signiﬁcantly different between the treat-
ment arms.
Conclusion: The results of this study suggest that
minocycline could be a tolerable and effective adju-
vant in the management of patients with OCD.
Key words: ﬂuvoxamine, glutamate, minocycline,
obsessive–compulsive disorder, trial.
O BSESSIVE–COMPULSIVE DISORDER (OCD)affects 1–3% of the world population. Gener-
ally, it has an early age onset during childhood or
early adult life.1–3 The course of illness is waxing
and waning chronically if left untreated.4,5 OCD
severely impairs quality of life in patients.6
Cognitive-behavioral therapy in the form of exposure
and response prevention (ERP) and medication man-
agement are the mainstay of treatment for OCD.
OCD ﬁrst-line medications are serotonin reuptake
inhibitors (SRI).7,8 SRI usually decrease the severity
of OCD symptoms by as much as 20–30%.9 Satisfac-
tory treatment is obtained in 40–60% of OCD
patients.10–12 Therefore, focus of many trials has been
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on the development of novel agents in the pharma-
cotherapy of OCD.11–15 Several lines of evidence sug-
gest that OCD can be caused by glutamatergic
dysfunction in orbitofrontal/basal ganglia brain cir-
cuits.16,17 Neuroimaging studies demonstrated reduc-
tion of glutamatergic neurotransmission in the
anterior cingulate cortex of OCD patients.18 Gluta-
mate in the cerebrospinal ﬂuid (CSF) of OCD
patients is increased and this provides evidence in
support of the neurobiological models of OCD.19 In
previous studies, 30–54% of OCD patients
responded to glutamate modulators as an augmenta-
tion agent to SRI.20–24 Minocycline is the most
widely prescribed antibiotic for chronic acne due to
lower antibiotic resistance compared to other tetracy-
clines and antimicrobials.25 Minocycline passes the
blood–brain barrier. Prior trials have shown neuro-
protective effects of minocycline in amyotrophic
lateral sclerosis and Parkinson’s disease.26,27 In ani-
mal studies, minocycline has been reported to signiﬁ-
cantly reduce 3,4-methylenedioxymethamphetamine-
induced neurotoxicity of 5-hydroxytryptamine and
dopamine systems in the cerebral cortex and hippo-
campus and to promote neurogenesis.28 Minocycline
has a regulatory effect on pro-inﬂammatory agents,
including nitric oxide, tumor necrosis factor-α, and
interleukin-1β.29 Animal studies have shown that
minocyclines decrease glutamate-induced neurotoxic-
ity.30 Minocycline has therapeutic effects on neurode-
generative diseases and this might be achieved
through the blockade of glutamate-mediated excito-
toxicity.31 Moreover, this antibiotic is known for its
antioxidant and anti-inﬂammatory characteristics,
which could further explain its neuroprotective
effects.32 Previously, we have demonstrated the bene-
ﬁcial role of minocycline in improving symptoms of
schizophrenia, depressive and autistic
symptoms.33–35 The present study was conducted to
investigate the efﬁcacy and safety of minocycline as
an augmentative agent to ﬂuvoxamine, an SRI
strongly supported by OCD randomized trials in
treatment of moderate-to-severe OCD patients.36,37
METHODS
Trial setting and design
A 10-week, single-center, randomized, double-blind,
placebo-controlled, parallel-group trial was per-
formed in the outpatient clinic of Roozbeh Psychiat-
ric Hospital (teaching hospital of Tehran University
of Medical Sciences, Tehran, Iran) from March 2015
to January 2016. The trial was approved by the eth-
ics committee of Tehran University of Medical Sci-
ence (Grant No.: 27224) and conducted according
to the Declaration of Helsinki and subsequent
revisions. Written informed consent was obtained
from all subjects before participation. Patients were
informed that their participation was voluntary
and that they could withdraw from the trial at any
time with no negative effect on their treatment.
The trial was registered at the Iranian Registry of
Clinical Trials (www.irct.ir; registration number:
IRCT201501031556N70).
Participants
Patients, aged 18–50 years, with a clinical diagnosis
of OCD according to the DSM-IV-TR, were screened
for the study. Those with a diagnosis of moderate-
to-severe OCD deﬁned by a Yale–Brown Obsessive
Compulsive Scale (Y-BOCS) score of ≥21 were
included.38,39
Patients were excluded from the study if they had
any other comorbid DSM-IV axis I disorders, serious
medical or neurological condition, substance
dependence (other than caffeine or nicotine), men-
tal retardation (based on clinical judgment), preg-
nancy, breast-feeding, or any contraindication for
the use of minocycline or ﬂuvoxamine, hepatic or
renal disease, seizure, lupus, neutropenia, anemia,
thrombocytopenia, head trauma, history of previous
psychosurgery for OCD, or any hypersensitivity to
the tetracycline antibiotics group. During the course
of the trial, patients were not allowed to participate
in psychotherapeutic sessions. Patients were also
excluded if they had received any psychotropic
drugs in the previous 6 weeks.
Interventions
Eligible participants were randomized to receive
either minocycline (Hexal, 100-mg tablet), 100 mg
twice per day, or placebo for 10 weeks. All partici-
pants, regardless of group assignment, also received
ﬂuvoxamine (Sobhan, 50-mg and 100-mg tablets),
100 mg/day for 28 days, followed by 200 mg/day
for the rest of the trial.
Outcome
Y-BOCS was used to evaluate treatment efﬁcacy. This
is a well-validated 10-item rating scale, which is
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widely used to measure the severity of OCD symp-
toms and has also been applied in several clinical
trials in Iran.11–14 Participants were rated by Y-BOCS
at baseline and at weeks 4 and 10.
The main outcome measure was difference in
score change of the Y-BOCS total score from the
baseline to the end of the trial between the two
groups. Differences in score change of the Y-BOCS
Obsession and Compulsion subscales from baseline
to week 10 as well as differences in score change of
total and subscale scores from baseline to other
time-points were assigned as secondary outcome
measures. Other secondary outcome measures
included differences in partial response rates
(deﬁned as ≥25% reduction in Y-BOCS score), com-
plete response rates (≥35% reduction in Y-BOCS
score) and remission rates (score ≤16) between the
two groups.40 Regarding the adverse events, partici-
pants were strongly encouraged to contact the study
team about any unexpected adverse events occurring
during the use of the drugs. Adverse events were
recorded using a structured checklist at each visit.
Participants were ﬁrst asked an open-ended question
about the occurrence of any adverse event. Further-
more, all patients received a phone call 1 week after
treatment initiation to evaluate possible adverse
effects. All participants underwent a thorough physi-
cal examination and measurement of a complete
blood count (CBC), liver and kidney function test
values at baseline and at each post-baseline visit.
Sample size
With the assumption of a difference of four points
on Y-BOCS scores between the minocycline and the
placebo groups, an SD of 5, a two-sided signiﬁcance
level of 0.05, and a statistical power of 95%, a sam-
ple size of 84 (each group 42) was calculated.
Predicting a dropout rate of 20%, a total number of
102 participants were needed.
Randomization, allocation concealment,
and blinding
A computerized random-number generator was used
to allocate patients into two groups in a 1/1 ratio
(blocks of 4). The assignments were concealed in
sequentially numbered sealed, opaque envelopes.
Minocycline and placebo capsules had similar
appearance, shape, size, texture, color and odor.
Random allocation was performed by an
independent person who was not involved else-
where in the trial. The patients, the psychiatrists
who rated them and prescribed the medication, and
the statistician were all blind to allocation.
Statistical analysis
Data analysis was carried out using SPSS 22 (SPSS,
Chicago, IL, USA). Numerical variables were sum-
marized by using mean  SD and categorical vari-
ables were presented as number of patients and
percentages. Normally distributed continuous vari-
ables were compared between the minocycline and
the placebo groups using the Independent t-test. The
mean difference (MD) between the minocycline
group and the placebo group was reported as MD,
95% conﬁdence interval (CI). Two-factor repeated-
measure ANOVA was used to evaluate time × treat-
ment interaction between the treatment groups. The
Greenhouse–Geisser adjustment was performed,
when Mauchly’s test of sphericity indicated that the
assumption of sphericity had been violated. After
controlling for baseline Y-BOCS scores, ANCOVA was
used to compare Y-BOCS scores between the groups
at the trial end. Cohen’s d effect size was calculated
to quantify the treatment effect. The χ2 or Fisher’s
exact tests were used to compare proportions
between the two groups as appropriate. All of the
above-mentioned statistical analyses were performed
two-sided, and P < 0.05 was considered as
signiﬁcant.
RESULTS
Patients
A total of 126 patients were screened for eligibility
criteria. One hundred and two patients were ran-
domly assigned to receive either minocycline plus
ﬂuvoxamine (n = 51) or placebo plus ﬂuvoxamine
(n = 51). Eight patients discontinued the trial (four
patients in each group) and a total of 94 patients
(47 in each group) completed the trial (Fig. 1). Base-
line characteristics of the participants are summar-
ized in Table 1. At baseline, no patient suffered
from an infective disease that needed antibiotic
usage.
Y-BOCS total score
Y-BOCS total scores did not differ signiﬁcantly between
the two groups at baseline, MD (95%CI) = 0.36 (−0.90
© 2016 The Authors
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to 1.62), t (59.86) = 0.57, P = 0.56. Signiﬁcant effect
for time × treatment interaction, Greenhouse–Geisser
corrected: F(1.49, 137.93) = 7.1, P = 0.003 (Fig. 2),
was demonstrated by repeated-measure ANOVA. ANCOVA
demonstrated signiﬁcantly lower scores in the minocy-
cline group compared to the placebo group at the end
of the trial course, F(1, 91) = 7.24, P = 0.008
(Table 2), after controlling for baseline Y-BOCS total
score. At the end of the trial, signiﬁcantly higher remis-
sion rate, partial and complete response rates were
observed in the minocycline group compared to the
placebo group (Table 3). A signiﬁcantly shorter
126 patients screened
102 randomized
Discontinued:
2 withdrew consent at week 1
2 excluded due to substance
dependence at week 1
Discontinued:
4 withdrew consent
at week 1
51 assigned to fluvoxamine + minocycline
47 completed trial 47 completed trial
51 assigned to fluvoxamine + placebo
24 excluded before run in:
17 not meeting inclusion criteria
7 meeting exclusion criteria
Figure 1. Flow diagram of the study.
Table 1. Baseline characteristics according to the treatment group
Minocycline group Placebo group
(n = 47) (n = 47) P-value
Age (years), mean  SD 34.65  7.96 34.04  8.90 0.72
Sex, female, n (%) 29 (61.7%) 29 (61.7%) 1.00
Duration of the disease (years), mean  SD 4.48  2.61 5.27  2.92 0.17
Education
Primary and secondary school 14 (29.8%) 16 (34.0%) NS
Diploma 23 (48.9%) 15 (31.9%)
University degree 10 (21.3%) 16 (34%)
Single : married 15 (31.9%):32 (68.1%) 20 (42.6%):27 (57.4%) 0.28
Y-BOCS total score, mean  SD 29.93  4.03 29.57  1.58 0.56
Y-BOCS Obsession subscale score, mean  SD 15.93  2.14 15.42  1.19 0.15
Y-BOCS Compulsion subscale score,
mean  SD
13.93  2.64 14.14  0.97 0.60
NS, not signiﬁcant; Y-BOCS, Yale–Brown Obsessive Compulsive Scale.
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time was needed in the minocycline group than
the placebo group for partial response (P < 0.001), as
demonstrated by the Kaplan–Meier estimation (Fig. 3).
Y-BOCS Obsession subscale score
At baseline, Y-BOCS Obsession subscale scores did
not differ between the two groups, MD (95%CI) =
0.51 (−0.20 to 1.22), t (72.06) = 1.42, P = 0.15.
General linear model repeated measure demon-
strated signiﬁcant effect for time × treatment interac-
tion on Y-BOCS total score, F(1.54, 141.94) = 9.72,
P < 0.001 (Fig. 4). ANCOVA, after controlling for
baseline Y-BOCS Obsession subscale score, demon-
strated lower scores in the minocycline arm in
comparison with the placebo arm at the end of the
trial course, F(1, 91) = 9.81, P = 0.002 (Table 2).
Y-BOCS Compulsion subscale score
At baseline, Y-BOCS Compulsion subscale scores
did not differ between the two groups, MD (95%
CI) = −0.21 (−1.03 to 0.61), t (58.30) = −0.51,
P = 0.60. General linear model repeated measure
demonstrated a near signiﬁcant effect for time ×
treatment interaction on Y-BOCS total score, F
(1.27, 117.47) = 2.92, P = 0.08 (Fig. 5). ANCOVA,
after controlling for baseline Y-BOCS Compulsion
subscale score, demonstrated lower scores in the
minocycline group arm in comparison with the
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Figure 2. Repeated-measure analysis of variance for the effect
of two treatments on the Yale–Brown Obsessive Compulsive
Scale (Y-BOCS) total scores. P-values show the result of the
analysis of covariance for comparison of scores between the
two groups at each time interval after controlling for baseline
scores (mean  SD; *P < 0.05). NS, not signiﬁcant. ( )
Minocycline group. ( ) Placebo group.
Table 2. Comparison of the Y-BOCS total and subscales scores between two groups using analysis of covariance
Y-BOCS score
Minocycline
group
(n = 47)
Placebo
group
(n = 47)
Mean differences
minocycline–placebo
(95%CI)
Cohen’s
d
P-
value
Total (week 10) 17.21  3.57 20.42  7.35 3.21 (0.84–5.58) 0.56 0.008
Obsession (week 10) 8.53  2.34 10.69  4.12 2.12 (0.75–3.50) 0.64 0.002
Compulsion (week 10) 8.23  1.96 9.76  4.09 1.53 (0.21–2.84) 0.48 0.02
CI, conﬁdence interval; Y-BOCS, Yale-Brown Obsessive Compulsive Scale.
Table 3. Comparison of outcome indexes between the two groups
Outcome Minocycline group Placebo group P-value Odds ratio (95%CI)
Number (%) of PR at week 4 29 (61.7%) 12 (25.5%) <0.001 4.69 (1.94–11.33)
Number (%) of PR at week 10 40 (85.1%) 18 (38.3%) <0.001 9.20 (3.40–24.90)
Number (%) of CR at week 4 11 (23.4%) 8 (17.0%) 0.44 1.49 (0.53–4.11)
Number (%) of CR at week 10 36 (76.6%) 15 (31.9%) <0.001 6.98 (2.80–17.38)
Number (%) of remitters at week 4 7 (14.9%) 5 (10.6%) 0.53 1.47 (0.43–5.01)
Number (%) of remitters at week 10 23 (48.9%) 13 (27.7%) 0.03 2.50 (1.06–5.90)
CI, conﬁdence interval; CR, complete responders; PR, partial responders.
© 2016 The Authors
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placebo arm at the end of the trial course, F
(1, 91) = 5.04, P = 0.02 (Table 2).
Side-effects
Adverse events were recorded during the study. Side-
effects were mild and did not result in withdrawal.
Frequency of side-effects was not different between
the two groups (Table 4).
DISCUSSION
OCD results in impaired social and occupational
function of the patients.6 Data suggest that OCD
can be caused by glutamatergic dysfunction in orbi-
tofrontal/basal ganglia brain circuits.16,17 There is
increasing interest in augmentative strategies because0 2 4 6
Trial weeks
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Figure 4. Repeated-measure analysis of variance for the effect
of two treatments on the Yale–Brown Obsessive Compulsive
Scale (Y-BOCS) Obsession subscale scores. P-values show the
result of the analysis of covariance for comparison of scores
between the two groups at each time interval after controlling
for baseline scores (mean  SD; *P < 0.05). NS, not signiﬁ-
cant. ( ) Minocycline group. ( ) Placebo group.
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Figure 5. Repeated-measure analysis of variance for the effect
of two treatments on the Yale–Brown Obsessive Compulsive
Scale (Y-BOCS) Compulsion subscale scores. P-values show
the result of the analysis of covariance for comparison of
scores between the two groups at each time interval after con-
trolling for baseline scores (mean  SD; *P < 0.05). NS, not
signiﬁcant. ( ) Minocycline group. ( ) Placebo group.
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Figure 3. Comparison of time needed to partially respond to
treatment between the two groups. ( ) Minocycline group.
( ) Placebo group.
Table 4. Frequency of adverse events between treatment
groups
Minocycline
group
Placebo
group
Adverse event (n = 47) (n = 47) P-value
Diarrhea, n, % 6 (12.8) 3 (6.4) 0.48
Headache, n, % 4 (8.5) 3 (6.4) 1.00
Increased
appetite, n, %
5 (10.6) 7 (14.9) 0.53
Dizziness, n, % 4 (8.5) 5 (10.6) 1.00
Insomnia, n, % 3 (6.4) 4 (8.5) 1.00
Nausea, n, % 6 (12.8) 4 (8.5) 0.50
Sedation, n, % 5 (10.6) 6 (12.8) 0.74
Abdominal
pain, n, %
6 (12.8) 4 (8.5) 0.50
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a signiﬁcant number of OCD patients do not ade-
quately respond to the ﬁrst-line medication. Rosen-
berg et al. suggested a reversible glutamatergically
mediated impairment of the thalamo-cortical-striatal
pathway in OCD patients.41 Minocycline has neuro-
protective effects in different neurological diseases.42
Kuloglu et al. demonstrated a signiﬁcantly higher
level of malondialdehyde, a product of lipid peroxi-
dation, and glutathione peroxidase in OCD patients
compared to the control group.43 Experimental stud-
ies have consistently provided support for a deﬁcient
glutathione oxidative protective system in the ani-
mal model of OCD, especially in the frontal cor-
tex.44 The beneﬁcial effect of minocycline in OCD
patients is partly due to its anti-oxidative characteris-
tics, as oxidative stress is known to be associated
with OCD.45,46
Several lines of evidence implicate that OCD can
be caused by glutamatergic dysfunction in orbito-
frontal/basal ganglia brain circuits.47 These evi-
dences can be categorized into three main groups:
(i) the observation of changes in glutamate concen-
trations as assessed from CSF or by magnetic reso-
nance spectroscopy of the caudate anterior cingulate
cortex in patients with OCD; (ii) studies on animal
models with impaired glutamate signaling and con-
current phenotype resembling OCD; and (iii) the
ﬁnding of variations in genes involving the gluta-
mate pathway in patients with OCD.48 Studies have
shown signiﬁcantly higher glutamate concentrations
on the CSF of patients with OCD compared to con-
trols.19,49 Rosenberg et al. studied 11 psychotropic
drug-naïve children with OCD and showed signiﬁ-
cantly higher caudate glutamate concentrations in
patients in comparison with healthy controls.50
Inhibiting glutamate release has been associated
with reduction in OCD-like behavior in mice,51,52
and glutamate system dysregulation marked by
increased glutamate has been linked to compulsive
or repetitive behaviours.53 The neuroprotective effect
of minocycline against glutamate excitotoxicity,
through regulation of the p38 and Akt pathways, is
probably another mechanism by which minocycline
improves symptoms in patients with OCD.31 The
advantages of minocycline include low cost and US
Food and Drug Administration approval in adults
and children >12 years.25 It has an excellent side-
effect proﬁle. In a long-term placebo-controlled trial,
minocycline was given to Huntington’s disease
patients for 2 years and it was well-tolerated, with
no serious adverse effects.48 Previous studies have
demonstrated the beneﬁcial role of glutamate mod-
ulators, such as riluzole and memantine, as augmen-
tation agents to SRI.20–24,53–56 An open-label
augmentation trial of memantine, as a glutamatergic
agent, was conducted on 15 patients with treatment-
resistant OCD. Almost half the subjects had a mean-
ingful improvement in symptoms after 12 weeks.21
Ghaleiha et al. reported that memantine combina-
tion therapy with ﬂuvoxamine signiﬁcantly reduced
the obsessive–compulsive symptoms as quantiﬁed
with the Y-BOCS.12 The effect was evident in the
total score and the scores for the Obsession and
Compulsion subscales. Adding memantine to ﬂu-
voxamine in treatment of OCD also resulted in
more complete response in that study.11 In another
case–control study, memantine was found to be
effective as a glutamatergic-augmenting agent in
severe OCD.23 An open-label trial by Rodriguez
et al. assessed the effect of minocycline on nine
adult outpatients with Y-BOCS scores ≥16 despite a
therapeutic SRI dose.15 The patients were on stable
doses of SRI for at least 12 weeks and other con-
comitant psychotropic medications for at least
4 weeks prior to the study. In their trial, all patients
had failed at least one adequate trial of an antipsy-
chotic in the augmentation of an SRI. The authors
showed that minocycline augmentation of SRI phar-
macotherapy may not improve OCD in all adult
OCD patients, but may improve symptoms in those
with early-onset OCD and those with primary
hoarding.15 The difference between the ﬁndings of
Rodriguez et al. and the current trial might be due to
the different types of participants between the two
trials. Rodriguez et al. conducted their study on
treatment-resistant patients who had failed at least
one adequate trial of an antipsychotic in augmenta-
tion with an SRI, whereas the subjects of the current
trial were free from any psychiatric medication
6 weeks prior to the study.
In this study, minocycline was administrated with
a dosage of 100 mg twice daily with no serious
adverse events. The result showed that minocycline
signiﬁcantly reduced OCD symptoms as an adjuvant
agent to ﬂuvoxamine in moderate-to-severe OCD
patients compared to placebo. Several limitations of
this study should be addressed before overgeneraliz-
ing its ﬁndings. First, the study sample size was rela-
tively small. Second, the follow-up period was short
for trials of OCD, which are usually conducted over
a 12-week period, and this could partly explain the
lower complete response rate (≥35% reduction in
© 2016 The Authors
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the Y-BOCS score) of this trial (31.9%) compared to
a 12-week ﬂuvoxamine trial with a response rate of
45%. A long-term follow-up period is of great
importance as OCD is a chronic condition with a
high chance of several relapses during the course of
the disease.
Conclusion
The results of this 10-week double-blind
randomized-controlled trial suggest that minocy-
cline could be a safe and effective adjunctive treat-
ment for more rapid and greater improvement in
OCD symptoms. However, safety and efﬁcacy of
longer treatment periods with minocycline remain
to be determined.
ACKNOWLEDGMENTS
This study was supported by a grant from Tehran
University of Medical Sciences and Health Services
to Professor Shahin Akhondzadeh (Grant No:
27224). The funding organization had no role in
the design or conduct of the study; in the collection,
analysis, or interpretation of the data; or in the prep-
aration, review, or approval of the manuscript, or
the decision to submit the paper for publication.
DISCLOSURE STATEMENT
None of the authors contributing to this article has
any conﬂicts of interest to report.
AUTHOR CONTRIBUTIONS
Z.A., F.R., M.S., and M.R.S. participated in data
acquisition and the preparation of the manuscript.
M.R.N., S.E., and A.Z. performed data analysis and
wrote the manuscript. S.A. designed the manuscript,
provided the outlines for the presentation of the
study, supervised the study process and edited the
ﬁnal manuscript. All authors have reviewed the
process of data analysis, writing of the manuscript
and have approved the ﬁnal article.
REFERENCES
1. Karno M, Golding JM, Sorenson SB, Burnam MA. The epi-
demiology of obsessive–compulsive disorder in ﬁve US
communities. Arch. Gen. Psychiatry 1988; 45: 1094.
2. Sasson Y, Zohar J, Chopra M, Lustig M, Iancu I,
Hendler T. Epidemiology of obsessive–compulsive disor-
der: A world view. J. Clin. Psychiatry 1997; 58: 7–10.
3. Bogetto F, Venturello S, Albert U, Maina G, Ravizza L.
Gender-related clinical differences in obsessive–
compulsive disorder. Eur. Psychiatry 1999; 14: 434–441.
4. Thomsen PH. Obsessive–compulsive disorders. Eur. Child
Adolesc. Psychiatry 2012; 22: 23–28.
5. Mataix-Cols D, Rauch SL, Baer L et al. Symptom stability
in adult obsessive–compulsive disorder: Data from a nat-
uralistic two-year follow-up study. Am. J. Psychiatry 2002;
159: 263–268.
6. Albert U, Maina G, Bogetto F, Chiarle A, Mataix-Cols D.
Clinical predictors of health-related quality of life in
obsessive–compulsive disorder. Compr. Psychiatry 2010;
51: 193–200.
7. Seibell PJ, Hollander E. Management of obsessive–
compulsive disorder. F1000Prime Rep. 2014; 6: 68.
8. Foa EB, Liebowitz MR, Kozak MJ et al. Randomized,
placebo-controlled trial of exposure and ritual preven-
tion, clomipramine, and their combination in the treat-
ment of obsessive–compulsive disorder. Am. J. Psychiatry
2005; 162: 151–161.
9. Pigott TA, Seay SM. A review of the efﬁcacy of selective
serotonin reuptake inhibitors in obsessive–compulsive
disorder. J. Clin. Psychiatry 1999; 60: 101–106.
10. Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G,
Locatelli M, Bellodi L. Clinical predictors of drug
response in obsessive–compulsive disorder. J. Clin. Psy-
chopharmacol. 2001; 21: 488–492.
11. Askari N, Moin M, Sanati M et al. Granisetron adjunct to
ﬂuvoxamine for moderate to severe obsessive–
compulsive disorder: A randomized, double-blind,
placebo-controlled trial. CNS Drugs 2012; 26: 883–892.
12. Ghaleiha A, Entezari N, Modabbernia A et al. Memantine
add-on in moderate to severe obsessive–compulsive dis-
order: Randomized double-blind placebo-controlled
study. J. Psychiatr. Res. 2013; 47: 175–180.
13. Shalbafan M, Mohammadinejad P, Shariat SV et al. Cele-
coxib as an adjuvant to ﬂuvoxamine in moderate to
severe obsessive–compulsive disorder: A double-blind,
placebo-controlled, randomized trial. Pharmacopsychiatry
2015; 48: 136–140.
14. Heidari M, Zarei M, Hosseini SM et al. Ondansetron or
placebo in the augmentation of ﬂuvoxamine response
over 8 weeks in obsessive–compulsive disorder. Int. Clin.
Psychopharmacol. 2014; 29: 344–350.
15. Rodriguez CI, Bender J, Jr, Marcus SM, Snape M, Rynn M,
Simpson HB. Minocycline augmentation of pharmaco-
therapy in obsessive–compulsive disorder: An open-label
trial. J. Clin. Psychiatry 2010; 71: 1247–1249.
16. Pittenger C, Krystal JH, Coric V. Glutamate-modulating
drugs as novel pharmacotherapeutic agents in the treat-
ment of obsessive–compulsive disorder. NeuroRx 2006;
3: 69–81.
17. Graybiel AM, Rauch SL. Toward a neurobiology of
obsessive–compulsive disorder. Neuron 2000; 28:
343–347.
© 2016 The Authors
Psychiatry and Clinical Neurosciences © 2016 Japanese Society of Psychiatry and Neurology
524 S. Esalatmanesh et al. Psychiatry and Clinical Neurosciences 2016; 70: 517–526
18. Rosenberg DR, Mirza Y, Russell A et al. Reduced anterior
cingulate glutamatergic concentrations in childhood
OCD and major depression versus healthy controls.
J. Am. Acad. Child Adolesc. Psychiatry 2004; 43:
1146–1153.
19. Chakrabarty K, Bhattacharyya S, Christopher R,
Khanna S. Glutamatergic dysfunction in OCD. Neuropsy-
chopharmacology 2005; 30: 1735–1740.
20. Coric V, Taskiran S, Pittenger C et al. Riluzole augmenta-
tion in treatment-resistant obsessive–compulsive disor-
der: An open-label trial. Biol. Psychiatry 2005; 58:
424–428.
21. Aboujaoude E, Barry JJ, Gamel N. Memantine augmenta-
tion in treatment-resistant obsessive–compulsive disor-
der: An open-label trial. J. Clin. Psychopharmacol. 2009;
29: 51–55.
22. Laﬂeur DL, Pittenger C, Kelmendi B et al. N-acetylcysteine
augmentation in serotonin reuptake inhibitor refractory
obsessive–compulsive disorder. Psychopharmacology (Berl.)
2006; 184: 254–256.
23. Stewart SE, Jenike EA, Hezel DM et al. A single-blinded
case–control study of memantine in severe obsessive–
compulsive disorder. J. Clin. Psychopharmacol. 2010;
30: 34–39.
24. Feusner JD, Kerwin L, Saxena S, Bystritsky A. Differential
efﬁcacy of memantine for obsessive–compulsive disorder
vs. generalized anxiety disorder: An open-label trial. Psy-
chopharmacol. Bull. 2009; 42: 81–93.
25. Seukeran DC, Eady EA, Cunliffe WJ. Beneﬁt–risk assess-
ment of acne therapies. Lancet 1997; 349: 1251–1252.
26. Traynor BJ, Bruijn L, Conwit R et al. Neuroprotective
agents for clinical trials in ALS: A systematic assessment.
Neurology 2006; 67: 20–27.
27. NINDS NET-PD Investigators. A randomized, double-
blind, futility clinical trial of creatine and minocycline in
early Parkinson disease. Neurology 2006; 66: 664–671.
28. Zhang L, Shirayama Y, Shimizu E, Iyo M, Hashimoto K.
Protective effects of minocycline on 3,4-methylenedioxy-
methamphetamine-induced neurotoxicity in serotonergic
and dopaminergic neurons of mouse brain. Eur.
J. Pharmacol. 2006; 544: 1–9.
29. Lai AY, Todd KG. Hypoxia-activated microglial mediators
of neuronal survival are differentially regulated by tetracy-
clines. Glia 2006; 53: 809–816.
30. Morimoto N, Shimazawa M, Yamashima T, Nagai H,
Hara H. Minocycline inhibits oxidative stress and
decreases in vitro and in vivo ischemic neuronal damage.
Brain Res. 2005; 1044: 8–15.
31. Pi R, Li W, Lee NT et al. Minocycline prevents glutamate-
induced apoptosis of cerebellar granule neurons by differ-
ential regulation of p38 and Akt pathways. J. Neurochem.
2004; 91: 1219–1230.
32. Dean OM, Data-Franco J, Giorlando F, Berk M. Minocy-
cline: Therapeutic potential in psychiatry. CNS Drugs
2012; 26: 391–401.
33. Khodaie-Ardakani M-R, Mirshaﬁee O, Farokhnia M et al.
Minocycline add-on to risperidone for treatment of nega-
tive symptoms in patients with stable schizophrenia: Ran-
domized double-blind placebo-controlled study.
Psychiatry Res. 2014; 215: 540–546.
34. Emadi-Kouchak H, Mohammadinejad P, Asadollahi-
Amin A et al. Therapeutic effects of minocycline on mild-
to-moderate depression in HIV patients: A double-blind,
placebo-controlled, randomized trial. Int. Clin. Psycho-
pharmacol. 2016; 31: 20–26.
35. Ghaleiha A, Alikhani R, Kazemi MR et al. Minocycline as
adjunctive treatment to risperidone in children with
autistic disorder: A randomized, double-blind placebo-
controlled trial. J. Child Adolesc. Psychopharmacol. 2016.
doi: 10.1089/cap.2015.0175
36. Goodman WK, Price LH, Rasmussen SA, Delgado PL,
Heninger GR, Charney DS. Efﬁcacy of ﬂuvoxamine
in obsessive–compulsive disorder: A double-blind
comparison with placebo. Arch. Gen. Psychiatry 1989;
46: 36–44.
37. Freeman C, Trimble MR, Deakin J, Stokes TM, Ashford JJ.
Fluvoxamine versus clomipramine in the treatment of
obsessive compulsive disorder: A multicenter, rando-
mized, double-blind, parallel group comparison. J. Clin.
Psychiatry 1994; 55: 301–305.
38. Goodman WK, Price LH, Rasmussen SA et al. The Yale-
Brown Obsessive Compulsive Scale. II. Validity. Arch.
Gen. Psychiatry. 1989; 46: 1012–1016.
39. Goodman WK, Price LH, Rasmussen SA et al. The Yale-
Brown Obsessive Compulsive Scale. I. Development, use,
and reliability. Arch. Gen. Psychiatry 1989; 46:
1006–1011.
40. Pallanti S, Quercioli L. Treatment-refractory obsessive–
compulsive disorder: Methodological issues, operational
deﬁnitions and therapeutic lines. Prog. Neuropsychophar-
macol. Biol. Psychiatry 2006; 30: 400–412.
41. Rosenberg DR, MacMillan SN, Moore GJ. Brain anatomy
and chemistry may predict treatment response in paedia-
tric obsessive–compulsive disorder. Int.
J. Neuropsychopharmacol. 2001; 4: 179–190.
42. Domercq M, Matute C. Neuroprotection by tetracyclines.
Trends Pharmacol. Sci. 2004; 25: 609–612.
43. Kuloglu M, Atmaca M, Tezcan E, Gecici Ö, Tunckol H,
Ustundag B. Antioxidant enzyme activities and malon-
dialdehyde levels in patients with obsessive–compulsive
disorder. Neuropsychobiology 2002; 46: 27–32.
44. Güldenpfennig M, du Preez JL, Stein DJ, Harvey BH. Cor-
tico-striatal oxidative status, dopamine turnover and rela-
tion with stereotypy in the deer mouse. Physiol. Behav.
2011; 103: 404–411.
45. Simsek S, Gencoglan S, Yuksel T. DNA damage and anti-
oxidants in treatment naive children with obsessive–
compulsive disorder. Psychiatry Res. 2016; 237: 133–137.
46. Alici D, Bulbul F, Virit O et al. Evaluation of oxidative
metabolism and oxidative DNA damage in patients with
© 2016 The Authors
Psychiatry and Clinical Neurosciences © 2016 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences 2016; 70: 517–526 Minocycline in the treatment of OCD 525
obsessive–compulsive disorder. Psychiatry Clin. Neurosci.
2016; 70: 109–115.
47. Pittenger C, Bloch MH, Williams K. Glutamate abnormal-
ities in obsessive compulsive disorder: Neurobiology,
pathophysiology, and treatment. Pharmacol. Ther. 2011;
132: 314–332.
48. Wu K, Hanna GL, Rosenberg DR, Arnold PD. The role of
glutamate signaling in the pathogenesis and treatment of
obsessive–compulsive disorder. Pharmacol. Biochem.
Behav. 2012; 100: 726–735.
49. Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A,
Christopher R, Shankar S. Anti-brain autoantibodies and
altered excitatory neurotransmitters in obsessive–
compulsive disorder. Neuropsychopharmacology 2009; 34:
2489–2496.
50. Rosenberg DR, MacMaster FP, Keshavan MS,
Fitzgerald KD, Stewart CM, Moore GJ. Decrease in
caudate glutamatergic concentrations in pediatric
obsessive–compulsive disorder patients taking paroxe-
tine. J. Am. Acad. Child Adolesc. Psychiatry 2000; 39:
1096–1103.
51. Iijima M, Kurosu S, Chaki S. Effects of agents targeting
glutamatergic systems on marble-burying behavior. Neu-
rosci. Lett. 2010; 471: 63–65.
52. Gomes FV, Casarotto PC, Resstel LB, Guimarães FS.
Facilitation of CB1 receptor-mediated neurotransmis-
sion decreases marble burying behavior in mice. Prog.
Neuropsychopharmacol. Biol. Psychiatry 2011; 35:
434–438.
53. Haghighi M, Jahangard L, Mohammad-Beigi H et al. In
a double-blind, randomized and placebo-controlled
trial, adjuvant memantine improved symptoms in inpa-
tients suffering from refractory obsessive–compulsive
disorders (OCD). Psychopharmacology (Berl.) 2013; 228:
633–640.
54. Grant PJ, Joseph LA, Farmer CA et al. 12-week, placebo-
controlled trial of add-on riluzole in the treatment of
childhood-onset obsessive–compulsive disorder. Neurop-
sychopharmacology 2014; 39: 1453–1459.
55. Emamzadehfard S, Kamaloo A, Paydary K et al. Riluzole
in augmentation of ﬂuvoxamine for moderate to severe
obsessive compulsive disorder: Randomized, double-
blind, placebo-controlled study. Psychiatry Clin. Neurosci.
2016; 70: 332–341.
56. Pittenger C, Bloch MH, Wasylink S et al. Riluzole aug-
mentation in treatment-refractory obsessive–compulsive
disorder: A pilot randomized placebo-controlled trial.
J. Clin. Psychiatry 2015; 76: 1075–1084.
© 2016 The Authors
Psychiatry and Clinical Neurosciences © 2016 Japanese Society of Psychiatry and Neurology
526 S. Esalatmanesh et al. Psychiatry and Clinical Neurosciences 2016; 70: 517–526
